Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Trial of Docetaxel Prednisone, and Pazopanib Combo in Patients With mCRPC

Publish date:: September 27, 2019

Key clinical point: Docetaxel Prednisone, and Pazopanib combo was tolerable at full doses and showed promising efficacy in relatively poor risk patients with metastatic castration-resistant prostate cancer (mCRPC).

Major finding: Objective response rate was 31%; median PFS was 14.1 months (95% confidence interval [CI]: 7.1 and 22.2); and overall survival was 18.6 months (95% CI: 11.8 and 22.2).

Study details: 36 men with mCRPC were treated over 6 dose levels in a 2-site phase 1b Department of Defense Prostate Cancer Clinical Trials Consortium trial of docetaxel, prednisone, and pazopanib, once daily and ongoing androgen deprivation therapy and prophylactic pegfilgrastim.

Citation:

George D, et al. Prostate. 2019 Sep 9. doi: 10.1002/pros.23899.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Prostate Cancer

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,